Mecasermin

Mecasermin rinfibate (Iplex and Increlex ) is the only recombinant once-daily IGF-I replacement therapy for the treatment of growth failure in children with severe primary IGF-I deficiency or with GH gene deletions who have developed neutralizing antibodies to GH. This product has not been evaluated in patients with GH deficiency aside from the genetic abnormalities. [Pg.713]

Increlex (mecasermin, rh IGF-1) Growth failure in children Tercica/Baxter... [Pg.266]

Iplex (mecasermin rinfabate, complex Growth failure in children Insmed... [Pg.266]

A small number of children with growth failure have severe IGF-1 deficiency that is not responsive to exogenous GH. Causes include mutations in the GH receptor and development of neutralizing antibodies to GH. In 2005, the FDA approved mecasermin for treatment of severe IGF-1 deficiency that is not responsive to GH. Mecasermin is a complex of recombinant human IGF-1 (rhIGF-1) and recombinant human insulin-like growth factor-binding protein-3 (rhIGFBP-3). [Pg.832]

The most important adverse effect observed with mecasermin is hypoglycemia. To avoid hypoglycemia, the prescribing instructions require consumption of a meal or snack 20 minutes before or after mecasermin administration. Several patients have experienced intracranial hypertension and asymptomatic elevation of liver enzymes. [Pg.832]

Mecasermin Recombinant form of IGF-1 that stimulates IGF-1 receptors Restores normal growth and metabolic IGF-1 effects in individuals with IGF-1 deficiency Replacement in IGF-1 deficiency that is not responsive to exogenous GH SC injection 2 x/d also contains recombinant human IGF-binding protein-3, which prolongs the half-life of the rIGF-1 Toxicity Hypoglycemia, intracranial hypertension, increased liver enzymes... [Pg.846]

Parenteral 60, 90, 120 mg in single-use prefilled syringe for subcutaneous injection Mecasermin rinfabate (Iplex)... [Pg.848]

Mecasermin (rIGF-1) Increlex (Tercica/Genentech) Growth failure (IGF-1 deficiency)... [Pg.270]

Japan mecasermin protein Somazon Recombinant IGF-1 expressed in E. coli Anti-diabetic... [Pg.469]

Matrix-assisted laser desorption ionization time of flight, see MALDI-TOF Matrix-assisted laser desorption ionization time of flight mass spectrometry, see MALDI-TOF-MS Maximum plasma concentration 51 Maytansanoids, cytotoxic 1172 MCFD2 427 MDRl 58 Meal insulin 1454 Measles-mumps-rubella vaccine 1421 Mecasermin 465... [Pg.1866]

Mecasermin rhIGF-1 Growth failure secondary to severe primary IGF-1 deficiency Hypoglycemia, intracranial hypertension, transaminas elevations, otitis, cardia murmur... [Pg.456]

Insulin-like growth factor 1/insulin 36.4 growth factor-binding protein 3 complex IGF-1/IGFBP-3 mecasermin rinfabate (IPLEX)... [Pg.348]

Insulin-like growth factor (mecasermin) [SED-15, 1792 SEDA-32, 676]... [Pg.772]

Injectable recombinant human insulin-like growth factor (rhIGF-I rINN mecasermin) has been available for nearly 20 years for treatment of the rare instances of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies. It has also been used as an insulin-sensitizing agent in severe insulin-resistant conditions. Adverse reactions to mecasermin have been reviewed [24 ]. The most common adverse reaction is hypoglycemia, which is readily controlled by administration with meals. [Pg.772]

Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther 2009 26(1) 40-54. [Pg.796]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...